Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.
Lopardo G, Belloso WH, Nannini E, Colonna M, Sanguineti S, Zylberman V, Muñoz L, Dobarro M, Lebersztein G, Farina J, Vidiella G, Bertetti A, Crudo F, Alzogaray MF, Barcelona L, Teijeiro R, Lambert S, Scublinsky D, Iacono M, Stanek V, Solari R, Cruz P, Casas MM, Abusamra L, Luciardi HL, Cremona A, Caruso D, de Miguel B, Lloret SP, Millán S, Kilstein Y, Pereiro A, Sued O, Cahn P, Spatz L, Goldbaum F; INM005 Study Group. Lopardo G, et al. Among authors: lebersztein g. EClinicalMedicine. 2021 Apr;34:100843. doi: 10.1016/j.eclinm.2021.100843. Epub 2021 Apr 11. EClinicalMedicine. 2021. PMID: 33870149 Free PMC article.
Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.
Madera S, Chervo MF, Chiauzzi VA, Pereyra MG, Venturutti L, Izzo F, Roldán Deamicis A, Guzman P, Dupont A, Roa JC, Cenciarini ME, Barchuk S, Figurelli S, Lopez Della Vecchia D, Levit C, Lebersztein G, Anfuso F, Castiglioni T, Cortese E, Ares S, Deza EG, Gercovich FG, Proietti CJ, Schillaci R, Cordo Russo RI, Elizalde PV. Madera S, et al. Among authors: lebersztein g. Horm Cancer. 2020 Oct;11(5-6):218-239. doi: 10.1007/s12672-020-00392-4. Epub 2020 Jul 6. Horm Cancer. 2020. PMID: 32632815 Free PMC article.
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: lebersztein g. Cell Death Dis. 2022 May 9;13(5):447. doi: 10.1038/s41419-022-04855-0. Cell Death Dis. 2022. PMID: 35534460 Free PMC article.
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, Petrillo E, Merin SS, De Martino M, Montero D, Levit C, Lebersztein G, Anfuso F, Roldán Deamicis A, Mercogliano MF, Proietti CJ, Schillaci R, Elizalde PV, Cordo Russo RI. Madera S, et al. Among authors: lebersztein g. Cell Death Dis. 2023 Dec 15;14(12):833. doi: 10.1038/s41419-023-06339-1. Cell Death Dis. 2023. PMID: 38102106 Free PMC article. No abstract available.
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
Bruni S, Mauro FL, Proietti CJ, Cordo-Russo RI, Rivas MA, Inurrigarro G, Dupont A, Rocha D, Fernández EA, Deza EG, Lopez Della Vecchia D, Barchuk S, Figurelli S, Lasso D, Friedrich AD, Santilli MC, Regge MV, Lebersztein G, Levit C, Anfuso F, Castiglione T, Elizalde PV, Mercogliano MF, Schillaci R. Bruni S, et al. Among authors: lebersztein g. J Immunother Cancer. 2023 Mar;11(3):e005325. doi: 10.1136/jitc-2022-005325. J Immunother Cancer. 2023. PMID: 36889811 Free PMC article.